Quick Answer
Tango Therapeutics, Inc. reported Net Income Loss of -$101.59 million for the year ending 2025.
- Tango Therapeutics, Inc. showed an increase of +22.0% in Net Income Loss from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Tango Therapeutics, Inc.'s Net Income Loss has declined by 95.5%.
- Historical annual values: Fiscal year 2025: -$101.59 million | Fiscal year 2024: -$130.30 million | Fiscal year 2023: -$101.74 million | Fiscal year 2022: -$108.18 million | Fiscal year 2021: -$58.24 million | Fiscal year 2020: -$51.97 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: